RVTY (Revvity Inc) — Analysis Report

Prepared: 2026-09-18 | Instrument: RVTY (NYSE, S&P 500 component) | Sector: Health Care | Industry: Health Care Equipment

1. Data Integrity Statement (read first)

All three external data tools (get_stock_data, get_verified_market_snapshot, get_indicators) were called and returned NO_DATA_AVAILABLE — external market data tools are disabled in this deployment. Consequences, applied rigorously throughout this report:

• The verified market snapshot was not obtainable, so per protocol no exact OHLCV, price levels, or indicator values are asserted anywhere in this report. Any such figure you may see elsewhere should be treated as unverified for this session.
• All quantitative reasoning below is sourced exclusively from the permitted documents: the QuantOrb money-flow engine snapshot (2026-09-17 session), the SEC 10-K excerpt (filed 2026-02-24), and the SEC 13F-HR snapshot (as of 2026-03-31).
• Where the documents are silent (recent price action, ATR, RSI, MACD values, earnings results, guidance), the report states: not available in provided documents.

Discrepancy flags: The get_indicators/get_stock_data outputs conflict with nothing, because they produced no data — there is no reconciled number to present and none has been invented. The QuantOrb engine snapshot is itself one session stale relative to "now" (it covers the 2026-09-17 US session, not 2026-09-18); the current session's money-flow state is not available in provided documents.

2. Instrument Profile (from SEC 10-K, filed 2026-02-24)

What the filing excerpt establishes about RVTY's business character:

• Business model: A leading provider of health science solutions delivering complete workflows "from discovery to development, and diagnosis to cure" — i.e., a life-sciences tools/diagnostics franchise rather than a single-product developer.
• Specialized focus areas (as filed): translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. This breadth implies exposure to both pharma/biotech R&D spending and clinical diagnostics demand.
• Global footprint: products and services marketed in more than 160 countries — meaningful geographic diversification (and FX exposure, though FX specifics are not available in provided documents).
• Scale: approximately 11,000 employees as of December 28, 2025; headquartered in Waltham, Massachusetts; listed on the NYSE as "RVTY"; component of the S&P 500 Index (relevant for index-flow dynamics).
• What the excerpt does not contain: the MD&A section provided is opening boilerplate (forward-looking-statements caution only). Revenue, margins, cash flow, segment results, and guidance are not available in provided documents. Additionally, the 8-K Item 2.02 (earnings press release) is not available — no such filing was found in the lookback window — so there is no recent earnings print to anchor fundamentals.

3. Quantitative Signal Read (QuantOrb money-flow engine, 2026-09-17 US session)

Three data points, and each carries distinct nuance:

1. MFI = 69.06. The Money Flow Index is a volume-weighted momentum oscillator; conventional convention flags >70 as overbought. At 69.06, RVTY sits just under that threshold — buying pressure is elevated and near overbought, but the reading itself is not yet an overbought print. The critical nuance: there is no MFI trajectory in the documents (no prior readings), so it is impossible to say from the documents whether this is rising toward, falling away from, or plateauing near 70. Treating 69.06 as "strong but unconfirmed-in-direction" is the defensible read.
2. Signal = CONTINUATION. The engine classifies the current regime as trend-continuation rather than reversal or breakout-ignition.
3. Signal strength = 0.5905. This is the most important nuance in the snapshot. A strength of ~0.59 is only modestly above neutral. This is a low-to-moderate-conviction continuation call — the kind of signal that argues for confirmation before execution rather than unilateral action. The engine snapshot explicitly notes this is a quantitative screen output, not a recommendation.

Synthesis: The quantitative picture is * constructive-leaning but not high-conviction*: strong volume-weighted buying pressure (MFI ~69) aligned with a continuation classification, tempered by a signal strength that hovers just above the midpoint and an MFI within roughly one point of the conventional overbought line. The regime question this poses — continuation with room to run, or late-stage pressure near exhaustion — is precisely what the indicator selection below is designed to resolve.

4. Institutional Ownership Tape (13F-HR, as of 2026-03-31)

Five tracked institutional filer rows in the dataset (a quarter-end snapshot subject to a statutory lag of up to 45 days — as of today, this data is roughly 5.5 months stale and reflects no Q2/Q3 2026 activity):

Nuanced observations:

• Directionally mixed but accumulation-weighted among holders with change data: two added (EdgePoint, Roubaix), one held flat (Cascade), one cut nearly half its position (Eversept). Among the four with comparable prior-quarter data, net tracked flow is +190,189 shares (265,204 + 2,908 − 77,923).
• Concentration caveat: EdgePoint's 8.8M-share position represents roughly 93% of the tracked share base (~9.46M shares across all five filers). The net-accumulation read is therefore overwhelmingly a story about one holder adding, not broad institutional conviction. The dataset is explicitly a tracked top-holder snapshot, not an exhaustive list of 13F filers, and no shares-outstanding or float figure is provided, so ownership percentages cannot be computed — not available in provided documents.
• The single reduction (Eversept, −47.9%) is small in absolute shares (77,923) but proportionally large for that holder — a full exit trajectory if repeated, though one quarter of data cannot establish a trend.
• Timeliness caveat: with the snapshot as of 2026-03-31 and today being 2026-09-18, two quarter-end cycles have passed without disclosed updates. This tape cannot be used to characterize current institutional sentiment — only sentiment as of Q1 2026 quarter-end.

5. Selected Indicator Set and Rationale (the core deliverable)

My role here is indicator selection for this specific market context: elevated-but-sub-overbought money flow (MFI 69.06), a moderate-strength CONTINUATION call (0.5905), and no verifiable price data in hand. I selected 8 indicators across trend, momentum, and volatility categories, chosen to (a) confirm or refute the engine's continuation call, (b) detect exhaustion before MFI breaches 70 decisively, and (c) supply the risk-management input the signal itself lacks:

1. close_200_sma — Long-term trend benchmark. The first gate: a CONTINUATION signal is only meaningful if the strategic trend direction is identified. Enables golden/death-cross context. It reacts slowly by design — used here for regime classification, not entry timing.
2. close_50_sma — Medium-term trend and dynamic support/resistance. Bridges the 200 SMA and short-term noise; a continuation thesis is most credible when price holds above a rising 50 SMA.
3. close_10_ema — Responsive short-term average for entry timing. With MFI at 69.06, the 10 EMA answers the timing question the engine can't: whether pullbacks are holding above short-term momentum support (continuation intact) or breaking it (early fade). Prone to noise — deliberately paired with the two slower averages as filters.
4. macd — Momentum trend-change detection via EMA differentials; crossovers and divergences are the primary early-warning system against a continuation signal that fails. Complements the volume-based MFI with a price-based momentum measure.
5. macds — MACD signal line, required to operationalize MACD crossovers as triggers. Selected as a pair with macd; macdh was excluded as redundant (the histogram is derivable from the pair).
6. rsi — Price-momentum overbought/oversold measure and direct complement to the engine's MFI (a volume-weighted cousin). If RSI and MFI diverge — e.g., RSI rolling over while volume-weighted MFI holds — that divergence is high-information. Caveat baked in: in strong trends RSI may remain extreme; cross-check with trend averages.
7. boll_ub — Bollinger upper band, the relevant band edge for this regime. With MFI near 70, the operative question is whether price is pressing the upper band (breakout continuation, bands may be ridden in strong trends) or rejecting it (exhaustion). boll (middle) and boll_lb (lower) were excluded as redundant for a continuation-regime screen — the lower band only becomes informative after a reversal is already underway.
8. atr — Average True Range for stop-loss placement and position sizing. This is the indispensable risk complement: neither the engine snapshot nor any document provides volatility data, and the signal carries no risk parameter. ATR is reactive, so it functions as a sizing/stops input, not a directional one.

Redundancy exclusions summary: macdh (implied by macd/macds pair), boll and boll_lb (band set reduced to the regime-relevant upper edge), and vwma (volume-weighting already embedded in the engine's MFI — double-counting volume weighting adds no independent information). Note the MFI itself is supplied by the engine snapshot but is not one of the selectable parameters, which is why rsi was selected as the closest selectable complement.

6. Conditional, Actionable Framework

Because no verified price or indicator values are available in this deployment, the actionable output takes the form of an explicit if/then decision framework — the structure a trader should apply once live indicator values are obtainable, keyed to the one verified quantitative anchor (MFI 69.06 / CONTINUATION / 0.5905):

• Base case: Treat CONTINUATION as the working hypothesis, not a trade trigger. Require confluence before acting: price above a rising close_50_sma and close_200_sma, macd above macds, and RSI confirming rather than diverging from the MFI's strong reading.
• Continuation-intact evidence: price holding above close_10_ema on pullbacks; MFI crossing and holding above 70 with price riding boll_ub (in strong trends, price can ride the band — a band-tag alone is not a short signal).
• Exhaustion warning triggers: MFI stalling/rolling over from the high-60s while rsi prints a bearish divergence against price; macd crossing below macds while price remains above the 50 SMA (momentum-led, trend-intact — early caution); a decisive close below close_10_ema with follow-through.
• Regime-failure trigger: loss of the close_50_sma on a closing basis with MACD confirmation — this would falsify the CONTINUATION call regardless of the engine output, given that call's modest 0.5905 strength.
• Risk management: all stops and sizing must be parameterized off the current atr value once obtainable — no ATR-based level, volatility figure, or percentage move can be stated here because not available in provided documents.
• Fundamental overlay: the business is diversified, globally distributed (>160 countries), and index-included — supportive of treating RVTY as an investable trend vehicle rather than a speculative event trade. However, with no 8-K Item 2.02 in the lookback window and no financial results in the provided excerpt, there is no recent earnings anchor; a fresh earnings print is a known unknown that could invalidate any technical framework at short notice.

7. Summary Table

Bottom line: The permitted documents paint RVTY as a diversified, globally scaled health-sciences franchise sitting in a constructive but low-conviction quantitative regime — MFI at 69.06 with a CONTINUATION signal whose 0.5905 strength is only modestly above neutral, and a stale, single-holder-dominated institutional tape from Q1 2026. Nothing in the documents justifies an unconfirmed entry, and nothing permits a price-level claim. The correct posture is: hold the framework above, obtain the eight selected indicators from a live data source, and act only on confluence — with atr-based sizing as the non-negotiable risk overlay.

Overall Sentiment: Neutral (Score: 5.2/10) Confidence: Low

RVTY Sentiment Report — week of 2026-09-11 to 2026-09-18

1. Source-by-source breakdown

News (Yahoo Finance, past 7 days): No news data available in provided documents for this window. No event-driven sentiment signal can be derived from headlines.

StockTwits: Unavailable in this deployment — no retail message feed, no Bullish/Bearish ratio, no labeled sentiment tags. The leading fast-moving retail signal is absent.

Reddit (r/wallstreetbets, r/stocks, r/investing): Unavailable in this deployment. All three communities are silent; no community discussion can be weighed.

Alternative quantitative/SEC sources actually available: - QuantOrb money-flow engine (2026-09-17 US session): MFI 69.06 with a CONTINUATION signal (strength 0.5905). This places the money-flow reading in the upper-middle band — positive but not extreme/overbought. It is a quantitative screen output, explicitly not a recommendation. - SEC 10-K (filed 2026-02-24): Confirms RVTY as a leading health-science solutions provider (multi-omics, biomarkers, imaging, informatics), NYSE-listed, S&P 500 component, ~11,000 employees, products in 160+ countries. Purely descriptive; no directional sentiment content in the excerpt. MD&A guidance specifics are not available in provided documents. - SEC 8-K Item 2.02: No earnings-related 8-K found in the lookback window — no fresh earnings event signal. - 13F-HR (as of 2026-03-31, subject to up to 45-day lag): Net accumulation among tracked filers: EdgePoint added +265,204 shares (+3.1%), Roubaix added +2,908 (+4.8%), Cascade unchanged, SG Capital comparison unavailable; Eversept cut -77,923 (-47.9%) from a small base. Dominant tracked holder EdgePoint adding is the standout signal, though the snapshot is stale (nearly two quarters old) and covers only 5 filer rows.

2. Cross-source divergences and alignments

No true cross-source divergence can be assessed because the three sentiment sources (news, StockTwits, Reddit) returned no data. The only alignment available is between the money-flow reading (MFI 69, CONTINUATION) and the (stale) institutional accumulation tilt from 13F data — both point mildly positive, but neither is a current-week sentiment measure.

3. Dominant narrative themes

• Money-flow momentum: The strongest available signal is the 2026-09-17 MFI 69.06 / CONTINUATION print, suggesting buying pressure carried through the most recent session.
• Steady institutional base: The 13F snapshot shows the largest tracked holder (EdgePoint) adding to its position, with only one small filer trimming — a modestly constructive, but dated, institutional picture.
• No event catalysts visible: With no news feed and no Item 2.02 8-K, there is no identified near-term catalyst in the provided documents.

4. Catalysts and risks

• Catalyst (potential): A CONTINUATION money-flow signal can extend if inflows persist; watch for confirmation in subsequent sessions (not available in provided documents).
• Risk: MFI in the high-60s approaching the 70s band means continued inflows could shade into overbought territory; a reversal would trigger the CONTINUATION signal's opposite case.
• Risk (data): Sentiment read is structurally blind this week — retail positioning, community narratives, and news-driven re-rating are all invisible.
• Risk (staleness): 13F data is a 2026-03-31 snapshot; positioning may have changed materially since, and Eversept's -47.9% trim shows some tracked holders are lightening up.
• Risk (fundamental): 10-K Risk Factors (Item 1A) are referenced but not included in the excerpts; specific risk content is not available in provided documents.

5. Summary table

6. Bottom line

Overall band Neutral with a slight upward tilt (score 5.2) driven only by the mildly positive money-flow print and stale institutional accumulation — not by any actual sentiment source, all three of which are silent this week. Confidence is low. The trader should treat this as an incomplete read: the CONTINUATION screen (explicitly not a recommendation) is the only live input, and it should be weighed alongside fundamentals, technicals, and a data-restored sentiment picture before any decision.

RVTY Analysis Report — News, Money Flow, and Macro Context

Analysis date: 2026-09-18 | Instrument: RVTY (Revvity Inc, NYSE; S&P 500 component; Health Care / Health Care Equipment)

1. Critical Deployment Notice — Data Availability

Before the analysis, a mandatory disclosure: all external data tools (get_news, get_global_news, get_macro_indicators, get_prediction_markets) returned NO_DATA_AVAILABLE in this deployment. Multiple calls were attempted across every category (company news for RVTY, global macro news, CPI, Fed funds rate, 10Y Treasury, unemployment, yield curve, Fed rate-cut and recession-2026 prediction markets), and all were rejected. Accordingly, this report is constructed exclusively from the permitted source documents provided in the analysis context:

• [FACTS] — QuantOrb money-flow engine snapshot for RVTY (2026-09-17 US session)
• [FILING] — SEC 10-K excerpt (filed 2026-02-24)
• [EIGHTK] — 8-K Item 2.02 status (none found in lookback window)
• [THIRTEENF] — 13F-HR holdings snapshot (as of 2026-03-31)

The following are not available in provided documents: RVTY-specific news over the past week, global macroeconomic news, all FRED macro indicator readings (CPI, core PCE, unemployment, Fed funds rate, 10Y Treasury, yield curve), prediction-market probabilities, RVTY share prices, valuation metrics, earnings figures, guidance, and the next earnings date.

2. Quantitative Money-Flow Signal (Primary Trading Evidence)

The most current, instrument-specific datapoint is the QuantOrb money-flow engine snapshot for the 2026-09-17 US session:

Interpretation (framed strictly against the supplied data):

• MFI at 69.06 sits just beneath the conventional 70 level that technicians treat as the overbought boundary. This is consistent with strong, sustained buying pressure — but it is also near exhaustion territory. The marginal room between 69.06 and 70 is thin; continuation trades initiated here carry asymmetric risk if the oscillator rolls over.
• CONTINUATION signal at 0.5905 strength (~59% confidence) indicates the engine's screen projects persistence of the prevailing move rather than a reversal. The strength reading is moderate-to-solid — above coin-flip, but not high-conviction.
• Explicit caveats from the source itself: this is a quantitative screen output, not a recommendation, and it reflects a single session (2026-09-17). One session of money-flow does not establish a durable trend, and the signal should not be extrapolated beyond its stated coverage window (2026-09-18 analysis date is one day removed from the snapshot).

Actionable takeaway: the only defensible, data-grounded stance on RVTY is that recent money flow leans bullish-in-continuation, with the caveat that the MFI reading is within roughly one point of overbought. Any long positioning premised on this signal warrants tight risk controls (defined stops, reduced sizing) precisely because the signal's own strength (0.5905) is not high-conviction and its window is one session.

3. Fundamental Context from the 10-K (filed 2026-02-24)

The 10-K excerpt supplies business-context grounding for what RVTY is, though no financial results, segment figures, or risk-factor details are available in provided documents:

• Business profile: Revvity describes itself as "a leading provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure." Focus areas cited in the filing: translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics.
• Scale and footprint: products and services marketed in more than 160 countries; approximately 11,000 employees as of December 28, 2025.
• Listing: NYSE under "RVTY"; component of the S&P 500 Index. This membership matters contextually — RVTY's flows are partially governed by index dynamics, though no index-flow data is available in provided documents.
• MD&A excerpt: the filing's Item 7 excerpt is boilerplate forward-looking-statements language only. It confirms risk factors exist in Item 1A but does not supply them — specific financial condition, results of operations, and risk disclosures are not available in provided documents.

Trading relevance: the 160+ country footprint means RVTY has structural exposure to global demand conditions, FX translation, and trade/geopolitical regimes — but the macro data needed to assess those exposures is not available in provided documents. This should be treated as a monitoring requirement rather than a conclusion.

4. Catalyst Check — 8-K Status

• No 8-K Item 2.02 (earnings/press release) filing was found in the lookback window. This is a negative finding within the lookback window only — it means no fresh reported-results 8-K is in the supplied evidence set. It is not evidence that no earnings event occurred or is scheduled; the next RVTY earnings date is not available in provided documents.
• Practical implication: the absence of a fresh 8-K Item 2.02 in the evidence means there is no newly disclosed earnings surprise to trade against. Traders should independently verify the earnings calendar through their own channels before positioning, as event risk around unverified dates cannot be ruled in or out from this evidence set.

5. Institutional Positioning — 13F-HR (as of 2026-03-31)

The quantorb filers dataset carries 5 institutional filer rows for RVTY, with positions as of the 2026-03-31 quarter-end (statutory lag of up to 45 days — meaning this snapshot is roughly 5.5 months stale as of the 2026-09-18 analysis date):

Reading the snapshot:

• Net direction among comparable filers is positive: the three filers with prior-quarter comparisons (EdgePoint, Eversept, Roubaix) net to +190,189 shares aggregate QoQ, driven overwhelmingly by EdgePoint's +265,204-share addition. EdgePoint's position (8.80M shares) dwarfs all other tracked filers combined, so this snapshot is effectively an EdgePoint story.
• One dissent: Eversept Partners nearly halved its position (−47.9%). It is small in absolute terms (84,854 shares) relative to EdgePoint, but a ~48% reduction is a deliberate bearish vote worth noting.
• Material staleness caveat: this data is a quarter-end snapshot as of 2026-03-31, subject to up-to-45-day statutory lag, and the dataset itself states it is "not an exhaustive list of 13F filers" and "not real-time portfolio data." It cannot tell us current institutional positioning as of September 2026 — and it is not available in provided documents whether these holders have since added, trimmed, or exited.

Actionable takeaway: the 13F evidence supports a mildly constructive institutional-read picture (largest tracked holder adding, two smaller holders adding/holding, one small holder sharply reducing), but its 5.5-month staleness severely limits its forward utility. Use it as background color, not as a trade trigger.

6. Macro and Event-Risk Environment

• All FRED macro indicators (CPI, core PCE, unemployment, Fed funds rate, 10Y Treasury, yield curve) — not available in provided documents. No inflation, labor-market, or rate-path assessment can be grounded in evidence here.
• Global news and geopolitical developments — not available in provided documents. No trade, tariff, or demand-environment assessment is possible from this evidence set.
• Prediction markets (Fed rate cut odds, recession-2026 probability, sector events) — not available in provided documents. No market-implied forward probabilities can be cited.

Given RVTY's 160+ country footprint disclosed in its 10-K, this macro blindness is a genuine limitation: rate-sensitive growth positioning, global health-science capex cycles, and FX translation effects are all channels through which RVTY plausibly has exposure, but none can be evidenced here. Traders should treat macro regime assessment as an open item requiring their own data sources before sizing positions.

7. Synthesis and Positioning Framework for RVTY

What the evidence supports: 1. A bullish-leaning, moderate-conviction money-flow signal (MFI 69.06, CONTINUATION, 0.5905) as of the most recent available session (2026-09-17) — the freshest and most trade-relevant datapoint. 2. No fresh earnings 8-K in the evidence window — no newly reported catalyst to trade against. 3. A constructive-leaning but stale institutional picture (Q1 2026 13F; EdgePoint adding, one small filer exiting). 4. A broad, globally diversified health-science franchise per the 10-K — but with zero current macro or news visibility.

What the evidence does not support: any price level, valuation, target, or macro-driven thesis. Those are not available in provided documents.

Suggested risk posture (framework, not a recommendation): if acting on the continuation signal, treat it as a momentum trade with (a) tight invalidation given MFI proximity to overbought, (b) reduced size reflecting 0.5905 signal strength, (c) verification of the earnings calendar independently before entry, and (d) awareness that a single-session signal can reverse without warning.

8. Key Points Summary Table

This report is based solely on the four permitted source documents and reflects tool-availability constraints as disclosed in Section 1. The QuantOrb signal is a quantitative screen output, not a recommendation, and no figure in this report has been fabricated or sourced outside the provided evidence.

Fundamental Research Report — Revvity Inc (RVTY)

Analysis date: 2026-09-18 | Ticker: RVTY (NYSE) | Sector/Industry: Health Care / Health Care Equipment

1. Data Availability Note (read first)

All four external data tools (get_fundamentals, get_balance_sheet, get_cashflow, get_income_statement) were invoked for RVTY and returned NO_DATA_AVAILABLE — external market data tools are disabled in this deployment. Accordingly, this report is built exclusively from the provided source documents: (a) the QuantOrb money-flow snapshot, (b) the SEC 10-K excerpt (filed 2026-02-24), (c) the 8-K lookback status, and (d) the 13F-HR holdings snapshot. Where a data point is not covered, I state that it is "not available in provided documents."

2. Company Profile (from SEC 10-K, filed 2026-02-24)

• Identity: Revvity Inc is a provider of health science solutions, technologies, expertise and services delivering complete workflows "from discovery to development, and diagnosis to cure."
• Specialized focus areas (as filed): translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics.
• Headquarters: Waltham, Massachusetts.
• Geographic reach: products and services marketed in more than 160 countries.
• Scale (headcount): approximately 11,000 employees as of December 28, 2025 — implying a fiscal year-end of December 28, 2025 (FY2025).
• Listing: Common stock on the New York Stock Exchange under "RVTY"; a component of the S&P 500 Index.
• Disclosure posture: the company makes its 10-K, 10-Q, 8-K and amendments available free via revvity.com, and explicitly does not incorporate website content into the 10-K.

Profile gaps: Segment structure, revenue by segment/geography, product-level mix, customers, and competitive positioning are not available in provided documents (the excerpt covers only the Item 1 opening and the Item 7 MD&A boilerplate).

3. Quantitative Flow Snapshot (QuantOrb money-flow engine, 2026-09-17 US session)

Interpretation, strictly bounded by the document: the engine characterizes the current money-flow state as a continuation condition at moderate-to-solid strength (0.5905), with MFI at 69.06 — elevated but not tagged as an extreme or reversal condition by the engine. Critically, the source itself states this is a quantitative screen output, not a recommendation. No price, volume, or market-cap data accompanies the snapshot; those are not available in provided documents.

4. Financial Statements & Financial History

• Income statement: not available in provided documents (tool disabled; the 10-K excerpt contains no financial figures).
• Balance sheet: not available in provided documents.
• Cash flow statement: not available in provided documents.
• Key ratios (margins, leverage, liquidity, returns): not available in provided documents.
• Recent earnings release: the 8-K lookback found no Item 2.02 press release in the window — i.e., no recent quarterly earnings press release is on file in the provided documents.

Filing cadence / staleness context: the most recent authoritative filing in the document set is the FY2025 10-K filed 2026-02-24 (fiscal year ended 2025-12-28), which is roughly seven months old as of the analysis date. Quarterly 10-Qs for FY2026 would ordinarily exist by now, but are not available in provided documents. The MD&A excerpt provided is forward-looking boilerplate only — no results discussion, guidance, or trend commentary is included.

Bottom line for traders: no valuation, margin, earnings, or leverage view can be responsibly formed from the provided evidence set. Any such view would require fabrication and is deliberately excluded.

5. Institutional Ownership (13F-HR, positions as of 2026-03-31)

Dataset scope: 5 institutional filer rows tracked by the quantorb filers dataset — explicitly not an exhaustive list of 13F filers. Subject to the statutory reporting lag of up to 45 days; as of the 2026-09-18 analysis date, this snapshot is well over five months stale (the June 30, 2026 quarter-end 13Fs are not in the provided dataset).

Derived observations (arithmetic on reported figures only): - Aggregate tracked position: ~9,461,229 shares across the 5 filers. - Concentration: EdgePoint alone holds ~93% of the tracked total — it is the dominant tracked holder, so its behavior drives the tracked-flow narrative. - Net tracked QoQ flow: +265,204 (EdgePoint) − 77,923 (Eversept) + 2,908 (Roubaix) + 0 (Cascade) = net +190,189 shares added among the four filers with comparable prior quarters. - Behavior pattern: three of four comparable filers held or added (EdgePoint +3.1%, Roubaix +4.8%, Cascade flat); the sole reducer, Eversept, cut -47.9% — but from a small base (implied prior position ~162,777 shares, roughly 1.7% of the tracked total), so its economic impact is minor. - Prior-quarter implied positions: EdgePoint ~8,535,659; Roubaix ~61,105 (derived from reported changes).

6. Actionable Insights for Traders

1. Flow posture is constructive, per the screen. The 2026-09-17 snapshot shows MFI 69.06 with a CONTINUATION tag at strength 0.5905 — a moderately strong continuation reading. Treat this as a screen signal, not a recommendation (per the source's own disclaimer), and note the documents provide no price/volume context to frame entry or risk levels.
2. Institutional tape leans net-positive but is stale and narrow. Net tracked accumulation of +190,189 shares QoQ, led by a +3.1% add from the dominant tracked holder (EdgePoint). However: (a) the snapshot is as of 2026-03-31 — over five months old; (b) only 5 filers are tracked, not the full 13F universe; and (c) 13F data is backward-looking regulatory disclosure, not real-time positioning. Do not overweight this as a current conviction signal.
3. The one bearish datapoint is economically small. Eversept's -47.9% cut looks alarming as a percentage but reflects ~77,923 shares — negligible versus EdgePoint's 8.8M-share position. It should not be read as broad institutional distribution.
4. Fundamental verification is blocked — treat valuation views as unformable. With no income statement, balance sheet, cash flow, ratios, or recent 8-K earnings release available, any P/E, margin, or leverage claim would be unsupported. Traders requiring fundamental confirmation should wait for the missing statements or an 8-K Item 2.02 earnings release before acting on the flow signal alone.
5. Key catalyst to watch: the next Item 2.02 earnings press release — none exists in the provided lookback window, so the market's freshest hard financial datapoint on file here is the FY2025 10-K narrative. A new release would be the first opportunity to validate fundamentals against the current flow signal.
6. Business-quality context (qualitative only): the 10-K describes a diversified, globally distributed health-science franchise (160+ countries, ~11,000 employees, S&P 500 constituent) — supportive of institutional interest in principle, but no quantitative quality metrics are available in provided documents.

7. Key Limitations

• No financial statement data, ratios, price, volume, market cap, guidance, segment detail, or risk-factor specifics: not available in provided documents.
• 13F snapshot is a partial, lagged view (2026-03-31; up to 45-day statutory lag; 5 filers only).
• The money-flow signal is a screen output, explicitly not a recommendation.
• 8-K Item 2.02: none found in the lookback window.

Summary Table of Key Points

Prepared for the RVTY fundamental-research workflow, 2026-09-18. All figures trace to the cited source documents; derived values are arithmetic on reported figures. Nothing herein is investment advice.